Business Context and Reporting Period
Castellum, Inc. (CTM) filed this Form 8-K on January 25, 2024, to report the entry into a material definitive agreement for a registered direct offering. The company is incorporated in Nevada and trades on the NYSE American. The offering is expected to close on or about January 29, 2024.
Key Financial Metrics and Offering Details
- Gross Proceeds: Approximately $2.7 million.
- Common Stock Issued: 5,243,967 shares at $0.32 per share.
- Pre-Funded Warrants Issued: 3,193,534 warrants at $0.319 per warrant, exercisable for an equal number of shares.
- Warrants Issued: 8,437,501 warrants to purchase common stock at an exercise price of $0.35 per share.
- Placement Agent Fees: 7.0% of aggregate gross proceeds plus reimbursement of legal fees up to $60,000.
- Warrant Terms: Warrants expire five years after shareholder approval and become exercisable upon such approval.
Material Changes and Restrictions
The filing details a significant capital raise intended to provide liquidity. The agreement includes specific market restrictions:
- Market Stand-Off: The Company agreed not to issue or announce the issuance of common stock or equivalents for 60 days following the closing, subject to exceptions.
- Variable Rate Transaction Restriction: The Company agreed not to enter into a Variable Rate Transaction for one year from the agreement date.
- Insider Lock-Up: Certain directors and officers are subject to a 60-day lock-up period following the closing.
Outlook, Risks, and Management Commentary
The offering is contingent upon the satisfaction of customary closing conditions. The Warrants issued in the private placement require shareholder approval to become exercisable. The filing references a press release (Exhibit 99.1) for further details on the pricing announcement. No specific operational risks or unusual items beyond the standard terms of the securities purchase agreement are detailed in this summary text.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Confirm the timeline and outcome of the required shareholder approval for the Warrants to become exercisable.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the market stand-off and lock-up provisions.
- Assess the dilution impact of the 5,243,967 shares, 3,193,534 pre-funded warrants, and 8,437,501 warrants on existing shareholders.